Strategic Director, Biostatistics

Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in Suresnes, France. Founded in 1954 by Jacques Servier, the company has grown from a small nine-person operation in Orléans, France, into a global enterprise employing over 22,000 people across 150 countries. Servier's unique governance model, being run by a foundation, allows it to operate with a long-term vision, free from the pressures of shareholders and short-term financial targets. This structure enables the company to reinvest close to 20% of its brand-name revenue back into research and development annually, a figure significantly higher than the industry average. This commitment to R&D fuels its mission of being dedicated to therapeutic progress to serve patient needs.

The company's research and development efforts are concentrated in key therapeutic areas with high unmet medical needs: oncology, cardiometabolism, neuroscience, and immuno-inflammatory diseases. Oncology has become a primary focus, with a significant portion of the R&D budget allocated to developing targeted and innovative therapies for difficult-to-treat cancers. Servier's portfolio includes both brand-name and generic medicines, ensuring broad access to quality healthcare. The company operates a global network of 14 production sites and 6 research centers, including a major R&D institute in Paris-Saclay. Servier is committed to open innovation, actively collaborating with academic institutions, startups, and other pharmaceutical companies to accelerate scientific progress. This patient-centric approach is integrated into every stage of the medicine lifecycle, from research to commercialization, aiming to improve not just treatment outcomes but also the overall quality of life for patients worldwide.